NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
Clinical Trials
40 trialsNCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT01723774 2025-12-09
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Washington University School of Medicine
Phase 2 Active not recruiting
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT02430480 2025-07-16
Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT00544830 2025-05-07
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT04862143 2024-06-20
TELEPIK
Novartis
Phase 2 Terminated
NCT03007979 2024-03-20
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Washington University School of Medicine
Phase 2 Completed
NCT01377389 2023-09-29
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02907918 2021-09-29
PALTAN
Washington University School of Medicine
Phase 2 Terminated
NCT02059213 2020-09-16
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02168062 2020-07-23
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT00937768 2019-12-27
Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Mayo Clinic
Phase 2 Terminated
NCT00186121 2019-10-07
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
Stanford University
Phase 2 Completed
NCT00298155 2018-08-09
TAPS
University of Washington
Phase 2 Completed
NCT00283803 2018-08-07
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Phase 2 Completed
NCT01776008 2018-05-08
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01496131 2018-03-09
Tecemotide (L-BLP25) in Prostate Cancer
EMD Serono
Phase 2 Completed
NCT01120236 2018-02-26
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00589472 2017-10-06
TARGET
National Cancer Institute (NCI)
Phase 2 Completed
NCT01023061 2017-06-06
RAD1
University of Washington
Phase 2 Completed
NCT00658697 2017-05-25
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01750398 2016-12-05
BAT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00081159 2016-11-10
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01076335 2016-09-19
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00016913 2016-07-06
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00586898 2016-03-25
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00454571 2016-02-10
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00500110 2015-04-28
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01368263 2015-04-03
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT01531205 2014-11-05
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01088529 2014-05-15
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
Cougar Biotechnology, Inc.
Phase 2 Completed
NCT01250717 2014-02-04
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00028769 2013-07-16
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT01205685 2012-09-11
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00322348 2011-01-24
Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women
AstraZeneca
Phase 2 Completed